Extracellular Vesicles in Molecular Diagnostics: An Overview with a Focus on CNS Diseases

Advances in Clinical Chemistry

Volumn 76, Issue , 2016, Pages 37-53

  Hirshman, B R ^a,b   Kras, R T ^a   Akers, J C ^a   Carter, B S ^a   Chen, C C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Carnegie Mellon University ^*  (United States)

Author keywords

Brain cancer; Exosome; Extracellular vesicle; Neurodegenerative diseases

Indexed keywords

BIOLOGICAL MARKER;

CENTRAL NERVOUS SYSTEM DISEASES; EXOSOME; HUMAN; RESEARCH; TRENDS;

BIOMARKERS; CENTRAL NERVOUS SYSTEM DISEASES; EXTRACELLULAR VESICLES; HUMANS; RESEARCH;

EID: 84999836293     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/bs.acc.2016.05.005     Document Type: Chapter

References (102)

1. [1] Gonda, D.D., Akers, J.C., Kim, R., et al. Neuro-oncologic applications of exosomes, microvesicles, and other nano-sized extra-cellular particles. Neurosurgery 72:4 (2013), 501–510.
2. [2] Théry, C., Zitvogel, L., Amigorena, S., Exosomes: composition, biogenesis and function. Nat. Rev. Immunol. 2:8 (2002), 569–579.
3. [3] Al-Nedawi, K., Meehan, B., Rak, J., Microvesicles: messengers and mediators of tumor progression. Cell Cycle 8:13 (2009), 2014–2018.
4. [4] Lai, C.P.-K., Breakfield, X.O., Role of exosomes/microvesicles in the nervous system and use in emerging therapies. Front. Physiol., 3, 2012, 228.
5. [5] Lee, T.H., D'Asti, E., Magnus, N., Al-Nedawi, K., Meehan, B., Rak, J., Microvesicles as mediators of intercellular communication in cancer—the emerging science of cellular “debris”. Semin. Immunopathol. 33:5 (2011), 445–467.
6. [6] Valadi, H., Ekström, K., Bossios, A., Sjöstrand, M., Lee, J.J., Lötvall, J.O., Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 9:6 (2007), 654–659.
7. [7] Johnstone, R.M., Adam, M., Hammond, J.R., Orr, L., Turbide, C., Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). J. Biol. Chem. 262:19 (1987), 9412–9420.
8. [8] Johnstone, R.M., Mathew, A., Mason, A.B., Teng, K., Exosome formation during maturation of mammalian and avian reticulocytes: evidence that exosome release is a major route for externalization of obsolete membrane proteins. J. Cell. Physiol. 147:1 (1991), 27–36.
9. [9] Frühbeis, C., Fröhlich, D., Krämer-Albers, E.-M., Emerging roles of exosomes in neuron–glia communication. Front. Physiol. 3 (2012), 1–7 article 119.
10. [10] Mostefai, H.A., Meziani, F., Mastronardi, M.L., et al. Circulating microparticles from patients with septic shock exert protective role in vascular function. Am. J. Respir. Crit. Care Med. 178:11 (2008), 1148–1155.
11. [11] Zhou, H., Pisitkun, T., Aponte, A., et al. Exosomal Fetuin-A identified by proteomics: a novel urinary biomarker for detecting acute kidney injury. Kidney Int. 70:10 (2006), 1847–1857.
12. [12] van Balkom, B.W.M., Pisitkun, T., Verhaar, M.C., Knepper, M.A., Exosomes and the kidney: prospects for diagnosis and therapy of renal diseases. Kidney Int. 80:11 (2011), 1138–1145.
13. [13] Properzi, F., Logozzi, M., Fais, S., Exosomes: the future of biomarkers in medicine. Biomark. Med. 7:5 (2013), 769–778.
14. [14] György, B., Szabó, T.G., Pásztói, M., et al. Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell. Mol. Life Sci. 68:16 (2011), 2667–2688.
15. [15] Ohno, S., Ishikawa, A., Kuroda, M., Roles of exosomes and microvesicles in disease pathogenesis. Adv. Drug Deliv. Rev. 65:3 (2013), 398–401.
16. [16] Nawaz, M., Fatima, F., Riedo Zanetti, B., et al. Microvesicles in gliomas and medulloblastomas: an overview. J. Cancer Ther., 5(2), 2015, 42790.
17. [17] Taylor, D.D., Gerçel-Taylor, C., MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol. Oncol. 110:1 (2008), 13–21.
18. [18] Zwicker, J.I., Liebman, H.A., Neuberg, D., et al. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin. Cancer Res. 15:22 (2009), 6830–6841.
19. [19] Tesselaar, M.E.T., Romijn, F.P.H.T.M., van der Linden, I.K., Prins, F.A., Bertina, R.M., Osanto, S., Microparticle-associated tissue factor activity: a link between cancer and thrombosis?. J. Thromb. Haemost. 5:3 (2007), 520–527.
20. [20] Akers, J.C., Gonda, D., Kim, R., Carter, B.S., Chen, C.C., Biogenesis of extracellular vesicles (EV): exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies. J. Neurooncol. 113:1 (2013), 1–11.
21. [21] Kalra, H., Simpson, R.J., Ji, H., et al. Vesiclepedia: a compendium for extracellular vesicles with continuous community annotation. PLoS Biol., 10(12), 2012, e1001450, 10.1371/journal.pbio.1001450.
22. [22] Bass, D.M., Baylor, M., Chen, C.C., Upadnyayula, U., Dansylcadaverine and cytochalasin D enhance rotavirus infection of murine L cells. Virology 212:2 (1995), 429–437.
23. [23] Théry, C., Oswrowski, M., Segura, E., Membrane vesicles as conveyors of immune responses. Nat. Rev. Immunol. 9 (2009), 581–593, 10.1038/nri2567.
24. [24] Cocucci, E., Racchetti, G., Meldolesi, J., Shedding microvesicles: artefacts no more. Trends Cell Biol. 19:2 (2009), 43–51.
25. [25] Jansen, F.H., Krijgsveld, J., van Rijswijk, A., et al. Exosomal secretion of cytoplasmic prostate cancer xenograft-derived proteins. Mol. Cell. Proteomics 8 (2009), 1192–1205.
26. [26] Kosaka, N., Iguchi, H., Yoshioka, Y., Takeshita, F., Matsuki, Y., Ochiya, T., Secretory mechanisms and intercellular transfer of microRNAs in living cells. J. Biol. Chem. 285:23 (2010), 17442–17452.
27. [27] Muralidharan-Chari, V., Clancy, J., Plou, C., et al. ARF6-regulated shedding of tumor cell-derived plasma membrane microvesicles. Curr. Biol. 19:22 (2009), 1875–1885.
28. [28] Santiago-Dieppa, D.R., Steinberg, J., Gonda, D., Cheung, V., Carter, B.S., Chen, C.C., Extracellular vesicles as a platform for “liquid biopsy” in glioblastoma patients. Expert. Rev. Mol. Diagn. 14:7 (2014), 819–825.
29. [29] Bartek, J. Jr., Ng, K., Bartek, J., Fischer, W., Carter, B.S., Chen, C.C., Key concepts in glioblastoma therapy. J. Neurol. Neurosurg. Psychiatry 83:7 (2012), 753–760.
30. [30] Kros, J.M., Mustafa, D.M., Dekker, L.J.M., Sillevis Smitt, P.A.E., Luider, T.M., Zheng, P.-P., Circulating glioma biomarkers. Neuro-Oncology 17:3 (2014), 343–360.
31. [31] Shao, H., Chung, J., Balaj, L., et al. Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nat. Med. 18:12 (2012), 1835–1840, 10.1038/nm.2994.
32. [32] Skog, J., Würdinger, T., van Rijn, S., et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat. Cell Biol. 10:12 (2008), 1470–1481.
33. [33] Salkeni, M.A., Zarzour, A., Ansay, T.Y., et al. Detection of EGFRvIII mutant DNA in the peripheral blood of brain tumor patients. J. Neurooncol. 115:1 (2013), 27–35.
34. [34] Chen, W.W., Balaj, L., Liau, L.M., et al. BEAMing and droplet digital PCR analysis of mutant IDH1 mRNA in glioma patient serum and cerebrospinal fluid extracellular vesicles. Mol. Ther. Nucleic Acids, 2(7), 2013, e109.
35. [35] Akers, J.C., Ramakrishnan, V., Kim, R., et al. miR-21 in the extracellular vesicles (EVs) of cerebrospinal fluid (CSF): a platform for glioblastoma biomarker development. PLoS One, 8(10), 2013, e78115, 10.1371/journal.pone.0078115.
36. [36] Zhang, W., Zhang, J., Hoadley, K., et al. miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression. Neuro-Oncology 14:6 (2012), 712–719.
37. [37] Akers, J.C., Ramakrishnan, V., Kim, R., et al. miRNA contents of cerebrospinal fluid extracellular vesicles in glioblastoma patients. J. Neurooncol. 123 (2015), 205–216.
38. [38] Kushwaha, D., Ramakrishnan, V., Ng, K., et al. A genome-wide miRNA screen revealed miR-603 as a MGMT regulating miRNA in glioblastomas. Oncotarget 5 (2014), 4026–4039.
39. [39] J.C. Akers, C.C. Chen, Unpublished lab data, July 2015.
40. [40] Fiandaca, M.S., Kapogiannis, D., Mapstone, M., et al. Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: a case-control study. Alzheimers Dement. 11:6 (2015), 600–607.
41. [41] Kapogiannis, D., Boxer, A., Schwartz, J.B., et al. Dysfunctionally phosphorylated type 1 insulin receptor substrate in neural-derived blood exosomes of preclinical Alzheimer's disease. J. Fed. Am. Soc. Exp. Biol. 29:2 (2014), 589–596.
42. [42] Goetzl, E.J., Boxer, A., Schwartz, J.B., et al. Low neural exosomal levels of cellular survival factors in Alzheimer's disease. Ann. Clin. Transl. Neurol. 2 (2015), 769–773.
43. [43] Goetzl, E.J., Boxer, A., Schwartz, J.B., et al. Altered lysosomal proteins in neural-derived plasma exosomes in preclinical Alzheimer disease. Neurology 85:1 (2015), 40–47.
44. [44] Yang, Y., Keene, D., Peskind, E.R., et al. Cerebrospinal fluid particles in Alzheimer disease and Parkinson disease. J. Neuropathol. Exp. Neurol. 74:7 (2015), 672–687.
45. [45] Fonteh, A.N., Cipolla, M., Chiang, J., Arakaki, X., Harrington, M.G., Human cerebrospinal fluid fatty acid levels differ between supernatant fluid and brain-derived nanoparticle fractions, and are altered in Alzheimer's disease. PLoS One, 9(6), 2014, e100519.
46. [46] Shi, M., Liu, C., Cook, T.J., et al. Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson's disease. Acta Neuropathol. 128:5 (2014), 639–650.
47. [47] Tomlinson, P.R., Zheng, Y., Fischer, R., et al. Identification of distinct circulating exosomes in Parkinson's disease. Ann. Clin. Transl. Neurol. 2:4 (2015), 353–361.
48. [48] Ho, D.H., Yi, S., Seo, H., Son, I., Seol, W., Increased DJ-1 in urine exosome of Korean males with Parkinson's disease. BioMed Res. Int., 2014, 2014, 704678.
49. [49] Sáenz-Cuesta, M., Irizar, H., Castillo-Triviño, T., et al. Circulating microparticles reflect treatment effects and clinical status in multiple sclerosis. Biomark. Med. 8:5 (2014), 653–661.
50. [50] Minagar, A., Jy, W., Jimenez, J.J., et al. Elevated plasma endothelial microparticles in multiple sclerosis. Neurology 56:10 (2001), 1319–1324.
51. [51] Sheremata, W.A., Jy, W., Horstman, L.L., Ahn, Y.S., Alexander, J.S., Minagar, A., Evidence of platelet activation in multiple sclerosis. J. Neuroinflammation, 5, 2008, e27, 10.1186/1742-2094-5-27.
52. [52] Jy, W., Minagar, A., Jimenez, J.J., et al. Endothelial microparticles (EMP) bind and activate monocytes: elevated EMP-monocyte conjugates in multiple sclerosis. Front. Biosci. 9 (2004), 3137–3144.
53. [53] Vella, L.J., Greenwood, D.L.V., Cappai, R., Scheerlinck, J.-P.Y., Hill, A.F., Enrichment of prion protein in exosomes derived from ovine cerebral spinal fluid. Vet. Immunol. Immunopathol. 124:2–3 (2008), 285–393.
54. [54] Robertson, C., Booth, S.A., Beniac, D.R., Coulthart, M.B., Booth, T.F., McNicol, A., Cellular prion protein is released on exosomes from activated platelets. Blood 107:10 (2006), 3907–3911.
55. [55] Fevrier, B., Vilette, D., Archer, F., et al. Cells release prions in association with exosomes. Proc. Natl. Acad. Sci. U.S.A. 101:26 (2004), 9683–9688.
56. [56] Raymond, A.D., Cambell-Sims, T.C., Kahn, M., et al. HIV type 1 Nef is released from infected cells in CD45þ microvesicles and is present in the plasma of HIV-infected individuals. AIDS Res. Hum. Retroviruses 27:2 (2011), 167–178.
57. [57] Hu, G., Yao, H., Chaudhuri, A.D., et al. Exosome-mediated shuttling of microRNA-29 regulates HIV Tat and morphine-mediated neuronal dysfunction. Cell Death Dis., 3(8), 2012, e381.
58. [58] Kanhai, D.A., Visseren, F.L.J., van der Graaf, Y., et al. Microvesicle protein levels are associated with increased risk for future vascular events and mortality in patients with clinically manifest vascular disease. Int. J. Cardiol. 168:3 (2013), 2358–2363.
59. [59] Lee, Y.J., Jy, W., Horstman, L.L., et al. Elevated platelet microparticles in transient ischemic attacks, lacunar infarcts, and multiinfarct dementias. Thromb. Res. 72:4 (1993), 295–304.
60. [60] Kuriyama, N., Nagakane, Y., Hosomi, A., et al. Evaluation of factors associated with elevated levels of platelet-derived microparticles in the acute phase of cerebral infarction. Clin. Appl. Thromb. Hemost. 16:1 (2010), 26–32.
61. [61] Jung, K.-H., Chu, K., Lee, S.-T., et al. Circulating endothelial microparticles as a marker of cerebrovascular disease. Ann. Neurol. 66:2 (2009), 191–199.
62. [62] Simak, J., Gelderman, M.P., Yu, H., Wright, V., Baird, A.E., Circulating endothelial microparticles in acute ischemic stroke: a link to severity, lesion volume and outcome. J. Thromb. Haemost. 4:6 (2006), 1296–1302.
63. [63] Lackner, P., Dietmann, A., Beer, R., et al. Cellular microparticles as a marker for cerebral vasospasm in spontaneous subarachnoid hemorrhage. Stroke 41 (2010), 2353–2357.
64. [64] Adamczak, S., Dale, G., de Rivero Vaccari, J.P., Bulloc, M.R., Dietrich, W.D., Keane, R.W., Inflammasome proteins in cerebrospinal fluid of brain injured patients are biomarkers of functional outcome. J. Neurosurg. 117:6 (2012), 1119–1125.
65. [65] Morel, N., Morel, O., Petit, L., et al. Generation of procoagulant microparticles in cerebrospinal fluid and peripheral blood after traumatic brain injury. J. Trauma 64:3 (2008), 698–704.
66. [66] de Rivero Vaccari, J.P., Brand, F. III, Adamczak, S., et al. Exosome-mediated inflammasome signaling after central nervous system injury. J. Neurochem. 136 (2015), 39–48, 10.1111/jnc.13036.
67. [67] Huttner, H.B., Corbeil, D., Thirmeyer, C., et al. Increased membrane shedding—indicated by an elevation of CD133-enriched membrane particles—into the CSF in partial epilepsy. Epilepsy Res. 99:1–2 (2012), 101–106.
68. [68] Ng, K., Kim, R., Kesari, S., Carter, B.S., Chen, C.C., Genomic profiling of glioblastoma: convergence of fundamental biologic tenets and novel insights. J. Neurooncol. 107:1 (2012), 1–12.
69. [69] Chiasserini, D., van Weering, J.R.T., Piersma, S.R., et al. Proteomic analysis of cerebrospinal fluid extracellular vesicles: a comprehensive dataset. J. Proteomics 106 (2014), 191–204.
70. [70] Colombo, E., Borgiani, B., Verderio, C., Furlan, R., Microvesicles: novel biomarkers for neurological disorders. Front. Physiol., 3, 2012, e63, 10.3389/fphys.2012.00063.
71. [71] Bellingham, S.A., Guo, B.B., Coleman, B.M., Hill, A.F., Exosomes: vehicles for the transfer of toxic proteins associated with neurodegenerative diseases?. Front. Physiol., 3, 2012, 124.
72. [72] Schneider, A., Simons, M., Exosomes: vesicular carriers for intercellular communication in neurodegenerative disorders. Cell Tissue Res. 352:1 (2014), 33–47.
73. [73] Vella, L.J., Sharples, R.A., Nisbet, R.M., Cappai, R., Hill, A.F., The role of exosomes in the processing of proteins associated with neurodegenerative diseases. Eur. Biophys. J. 37:3 (2008), 323–332.
74. [74] McKhann, G.M., Knopman, D.S., Chertkow, H., et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7:3 (2011), 263–269.
75. [75] Rajendran, L., Honsho, M., Zhan, T.R., et al. Alzheimer's disease β-amyloid peptides are released in association with exosomes. Proc. Natl. Acad. Sci. U.S.A. 103:30 (2006), 11172–11177.
76. [76] Saman, S., Kim, W., Raya, M., et al. Exosome-associated Tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. J. Biol. Chem. 287:6 (2012), 3842–3849.
77. [77] Craft, S., Cholerton, B., Baker, L.D., Insulin and Alzheimer's disease: untangling the Web. J. Alzheimers Dis. 33 (2013), S263–S275.
78. [78] Russo, I., Bubacco, L., Greggio, E., Exosomes-associated neurodegeneration and progression of Parkinson's disease. Am. J. Neurodegener. Dis. 1:3 (2012), 217–225.
79. [79] Sáenz-Cuesta, M., Osorio-Querejeta, I., Otaegui, D., Extracellular vesicles in multiple sclerosis: what are they telling us?. Front. Cell. Neurosci., 8, 2014, e100.
80. [80] Pusic, A.D., Pusic, K.M., Kraig, R.P., What are exosomes and how can they be used in multiple sclerosis therapy?. Expert. Rev. Neurother. 14:4 (2014), 353–355.
81. [81] Larkin, M., Raised endothelial microparticles an early marker for multiple sclerosis?. Lancet, 357(9269), 2001, 1679.
82. [82] Jimenez, J.J., Jy, W., Mauro, L.M., et al. Elevated endothelial microparticle–monocyte complexes induced by multiple sclerosis plasma and the inhibitory effects of interferon-β1b on release of endothelial microparticles, formation and transendothelial migration of monocyte-endothelial microparticle complexes. Mult. Scler. J. 11:3 (2005), 310–315.
83. [83] Verderio, C., Muzio, L., Turola, E., et al. Myeloid microvesicles are a marker and therapeutic target for neuroinflammation. Ann. Neurol. 72:4 (2012), 610–624.
84. [84] Gomes, C., Keller, S., Altevogt, P., Costa, J., Evidence for secretion of Cu, Zn superoxide dismutase via exosomes from a cell model of amyotrophic lateral sclerosis. Neurosci. Lett. 428:1 (2007), 43–46.
85. [85] Grad, L.I., Yerbury, J.J., Turner, B.J., et al. Intercellular propagated misfolding of wild-type Cu/Zn superoxide dismutase occurs via exosome-dependent and-independent mechanisms. Proc. Natl. Acad. Sci. U.S.A. 111:9 (2014), 3620–3625.
86. [86] Feneberg, E., Steinacker, P., Lehnert, S., et al. Limited role of free TDP-43 as a diagnostic tool in neurodegenerative diseases. Amyotroph. Lateral Scler. Frontotemporal Degener. 15:5–6 (2014), 351–356.
87. [87] Prusiner, S.B., Prions. Proc. Natl. Acad. Sci. U.S.A. 95:23 (1998), 13363–13383.
88. [88] Bellingham, S.A., Coleman, B.M., Hill, A.F., Small RNA deep sequencing reveals a distinct miRNA signature released in exosomes from prion-infected neuronal cells. Nucleic Acids Res. 40:21 (2012), 10937–10949.
89. [89] Zerr, I., Pocchiari, M., Collins, S., et al. Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt–Jakob disease. Neurology 55:6 (2000), 811–815.
90. [90] Kadiu, I., Narayananasamy, P., Dash, P.K., Zhang, W., Gendelman, H.E., Biochemical and biologic characterization of exosomes and microvesicles as facilitators of HIV-1 infection in macrophages. J. Immunol. 189:2 (2012), 744–754.
91. [91] Mfunyi, C.M., Vaillancourt, M., Vitry, J., et al. Exosome release following activation of the dendritic cell immunoreceptor: a potential role in HIV-1 pathogenesis. Virology 484:1 (2015), 103–112.
92. [92] Nguyen, D.G., Booth, A., Gould, S.J., Hildreth, J.E.K., Evidence that HIV budding in primary macrophages occurs through the exosome release pathway. J. Biol. Chem. 278 (2003), 52347–52354.
93. [93] Kim, S.J., Moon, G.J., Bang, O.Y., Biomarkers for stroke. J. Stroke 15:1 (2013), 27–37.
94. [94] Williams, J.B., Jauch, E.C., Lindsell, C.J., Campos, B., Endothelial microparticle levels are similar in acute ischemic stroke and stroke mimics due to activation and not apoptosis/necrosis. Acad. Emerg. Med. 14:8 (2007), 685–690.
95. [95] Taylor, D.D., Gerçel-Taylor, C., Exosome platform for diagnosis and monitoring of traumatic brain injury. Philos. Trans. R. Soc. Lond. B Biol. Sci., 369(1652), 2014, 20130503.
96. [96] Zetterberg, H., Smith, D.H., Blennow, K., Biomarkers of mild traumatic brain injury in cerebrospinal fluid and blood. Nat. Rev. Neurol. 9 (2013), 201–210.
97. [97] Graner, M.W., Epple, L.M., Dusto, N.L., Lencioni, A.M., Nega, M., Herring, M., Winston, B., Madsen, H., Bemis, L.T., Anchordoquy, T.J., Circulating exosomes as new biomarkers for brain disease and injury. Proc. SPIE 8723, Sensing Technologies for Global Health, Military Medicine, and Environmental Monitoring III, 87230R, May 29, 2013, 10.1117/12.2027435.
98. [98] Bhalala, O.G., Srikanth, M., Kessler, J.A., The emerging roles of microRNAs in CNS injuries. Nat. Rev. Neurol. 9:6 (2013), 328–339.
99. [99] Nieto-Diaz, M., Esteban, F.J., Reigada, D., et al. MicroRNA dysregulation in spinal cord injury: causes, consequences and therapeutics. Front. Cell. Neurosci., 8, 2014, 53, 10.3389/fncel.2014.00053.
100. [100] Hachisuka, S., Kamei, N., Ujigo, S., Miyaki, S., Yasunaga, Y., Ochi, M., Circulating microRNAs as biomarkers for evaluating the severity of acute spinal cord injury. Spinal Cord 52:8 (2014), 596–600.
101. [101] Hedge, M., Lowenstein, D.H., The search for circulating epilepsy biomarkers. Biomark. Med. 8:3 (2014), 413–427.
102. [102] Noerholm, M., Balaj, L., Limperg, T., et al. RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and controls. BMC Cancer, 12, 2012, 22.